Leslie J. Browne, PhD
Articles by Leslie J. Browne, PhD
| 4 min read
The recent approval of Novartis’ Tekturna marked the first new class of antihypertensive drugs to gain the FDA’s blessing in more than 15 years. This development clearly indicates that there continues to be a need for innovative treatments for hypertension despite the broad menu of therapies currently available.
Page 1 of 1 - 1 Total Items
Subscribe to our eNewsletters
Stay connected with all of the latest from Drug Discovery News.
SubscribeSponsored
Achieving bioanalytical precision and control
Advanced LIMS software helps researchers reliably manage complex bioanalytical workflows and data.
Maximizing NGS efficiency with magnetic beads
The latest magnetic bead technology cuts sample preparation time, producing consistent, reliable results.
Overcoming barriers in gene therapy
Advanced gene editing, delivery, and analytical tools are driving better gene therapies.
